Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health

Rejuvenate Bio, a biotechnology company focused on developing gene therapies for chronic and age-related diseases, has successfully closed a $6 million financing round. The funding round, which took place on June 11, 2026, was led by VCapital and included participation from notable investors such as Merck Animal Health, Connecticut Innovations, and Digitalis. Alongside the financing, Rejuvenate Bio announced a strategic research and development collaboration with Merck Animal Health aimed at advancing its gene therapy programs specifically designed for companion animals.

The proceeds from this financing round will be utilized to further develop Rejuvenate Bio's gene therapy platform and pipeline. The company is dedicated to creating innovative treatments that address chronic and age-associated diseases in companion animals, leveraging its proprietary technologies and expertise in translational science. The collaboration with Merck Animal Health is particularly significant, as it aims to enhance a novel gene therapy program that could potentially transform treatment options in the veterinary space.

Rejuvenate Bio's approach is rooted in modifying biological pathways associated with aging through targeted genetic interventions. The company has established a pipeline that not only focuses on veterinary applications but also has implications for human health, reflecting its dual commitment to addressing significant unmet needs in both sectors. Founded on research from the Wyss Institute at Harvard Medical School, Rejuvenate Bio is positioned at the intersection of biotechnology and veterinary medicine, aiming to pioneer solutions that extend healthy lifespans.

The involvement of Merck Animal Health as both an investor and collaborator underscores the strategic importance of this partnership. Merck's expertise in animal health, combined with Rejuvenate Bio's innovative gene therapy platform, creates a compelling synergy that could accelerate the development of effective therapies for chronic diseases in pets. This collaboration highlights a growing trend in the biotechnology sector where established pharmaceutical companies are increasingly investing in and partnering with innovative startups to enhance their product offerings and expand into new therapeutic areas.

The successful fundraising and collaboration come at a time when the biotechnology sector is witnessing heightened interest in gene therapies, particularly for age-related conditions. As the demand for effective treatments in both human and animal health continues to rise, Rejuvenate Bio's advancements may not only contribute to improved health outcomes for companion animals but also pave the way for future innovations in human healthcare. The broader market implications of this transaction suggest a positive outlook for companies focused on gene therapy and age-related disease treatment, as they attract investment and partnerships that can propel their research and development efforts forward.